The mission of the Gene Transfer and Somatic Cell Engineering (GTSC) Core is to develop, validate, and supply cell-based experimental products for Phase I and II clinical trials so that investigators can evaluate their safety and potential clinical benefit. In 2014, the GTSC Core moved to the Cell Therapy and Cell Engineering Facility (CTCEF), which opened when the Zuckerman II building was opened.
The aims of the GTSC Core have not changed. The Core supports the implementation of Phase I/II clinical trials based on cell engineering and adoptive cell therapies.
Its aims are as follows:
AIM1 : To develop SOPs and batch records for cell processing and engineering, vector production.
AIM2 : GMP manufacturing: Patient cell (expansion, purification, transduction, formulation); Vector stocks (plasmid DNA, cell banks).
AIM3 : Biosafety/release testing: Patient cells and vector stocks (e.g., phenotype, potency, purity, stability); Gene transfer/expression.
AIM4 : To monitor patients? samples post-infusion (e.g., FACS, Q-PCR).
AIM5 : To provide technological and regulatory expertise (GXP, FDA, RAC-NIH).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-55
Application #
10084821
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-20
Project End
2023-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
55
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Isharwal, Sumit; Huang, Hongying; Nanjangud, Gouri et al. (2018) Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. Hum Pathol 77:63-69
Ghuman, Marcus; Hwang, Sinchun; Antonescu, Cristina R et al. (2018) Plexiform fibrohistiocytic tumor: imaging features and clinical findings. Skeletal Radiol :
Kim, Jisun; Geyer, Felipe C; Martelotto, Luciano G et al. (2018) MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene. J Pathol 244:143-150
Neuschmelting, Volker; Kim, Kwanghee; Malekzadeh-Najafabadi, Jaber et al. (2018) WST11 Vascular Targeted Photodynamic Therapy Effect Monitoring by Multispectral Optoacoustic Tomography (MSOT) in Mice. Theranostics 8:723-734
Hyman, David M; Piha-Paul, Sarina A; Won, Helen et al. (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194
Turesson, Ingemar; Bjorkholm, Magnus; Blimark, Cecilie Hveding et al. (2018) Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. Eur J Haematol :
Moo, Tracy-Ann; Edelweiss, Marcia; Hajiyeva, Sabina et al. (2018) Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection? Ann Surg Oncol 25:1488-1494
Kinsley, Karen; Pritchett, Wendy (2018) Liposomal Irinotecan: Nursing Considerations in an Outpatient Cancer Center Clin J Oncol Nurs 22:221-224
Vargas, Hebert Alberto; Kramer, Gem M; Scott, Andrew M et al. (2018) Reproducibility and Repeatability of Semiquantitative 18F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. J Nucl Med 59:1516-1523
Ho, A L (2018) Developing androgen receptor targeting for salivary gland cancers. Ann Oncol 29:792-794

Showing the most recent 10 out of 8799 publications